82 related articles for article (PubMed ID: 38658988)
21. Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
Kenmotsu H; Wakuda K; Mori K; Kato T; Sugawara S; Kirita K; Yoneshima Y; Azuma K; Nishino K; Teraoka S; Shukuya T; Masuda K; Hayashi H; Toyozawa R; Miura S; Fujimoto D; Nakagawa K; Yamamoto N; Takahashi T
J Thorac Oncol; 2022 Sep; 17(9):1098-1108. PubMed ID: 35636696
[TBL] [Abstract][Full Text] [Related]
22. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Tan AC; Tan DSW
J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
[TBL] [Abstract][Full Text] [Related]
23. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA; Han JY; Dafni U; Cho BC; Yeo CM; Nadal E; Carcereny E; de Castro J; Sala MA; Bernabé R; Coate L; Provencio Pulla M; Garcia Campelo R; Cuffe S; Hashemi SMS; Früh M; Massuti B; Garcia-Sanchez J; Dómine M; Majem M; Sanchez-Torres JM; Britschgi C; Pless M; Dimopoulou G; Roschitzki-Voser H; Ruepp B; Rosell R; Stahel RA; Peters S;
Ann Oncol; 2022 Feb; 33(2):181-192. PubMed ID: 34839016
[TBL] [Abstract][Full Text] [Related]
24. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.
Tian X; Gu T; Lee MH; Dong Z
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188645. PubMed ID: 34793897
[TBL] [Abstract][Full Text] [Related]
25. Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.
Di Noia V; D'Aveni A; D'Argento E; Rossi S; Ghirardelli P; Bortolotti L; Vavassori V; Bria E; Ceresoli GL
ESMO Open; 2021 Dec; 6(6):100280. PubMed ID: 34634633
[TBL] [Abstract][Full Text] [Related]
26. Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level.
Wu Y; Yang S; Ma J; Chen Z; Song G; Rao D; Cheng Y; Huang S; Liu Y; Jiang S; Liu J; Huang X; Wang X; Qiu S; Xu J; Xi R; Bai F; Zhou J; Fan J; Zhang X; Gao Q
Cancer Discov; 2022 Jan; 12(1):134-153. PubMed ID: 34417225
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy.
Mikubo M; Inoue Y; Liu G; Tsao MS
J Thorac Oncol; 2021 Nov; 16(11):1798-1809. PubMed ID: 34352380
[TBL] [Abstract][Full Text] [Related]
28. Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.
Shaikh M; Shinde Y; Pawara R; Noolvi M; Surana S; Ahmad I; Patel H
J Med Chem; 2022 Jan; 65(2):1008-1046. PubMed ID: 34323489
[TBL] [Abstract][Full Text] [Related]
29. Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment.
Su PL; Tsai JS; Yang SC; Wu YL; Tseng YL; Chang CC; Yen YT; Lin CY; Lin CC; Wang CC; Lin MC; Su WC
Lung Cancer; 2021 Aug; 158():137-145. PubMed ID: 34214933
[TBL] [Abstract][Full Text] [Related]
30. S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation.
Liu S; Zhang H; Li Y; Zhang Y; Bian Y; Zeng Y; Yao X; Wan J; Chen X; Li J; Wang Z; Qin Z
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145030
[TBL] [Abstract][Full Text] [Related]
31. The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer.
Ferguson LP; Diaz E; Reya T
Trends Cancer; 2021 Jul; 7(7):624-634. PubMed ID: 33509688
[TBL] [Abstract][Full Text] [Related]
32. The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition.
Daum S; Hagen H; Naismith E; Wolf D; Pircher A
Front Cell Dev Biol; 2020; 8():610903. PubMed ID: 33469537
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
[TBL] [Abstract][Full Text] [Related]
34. Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study.
Cheng JT; Yao YH; Gao YE; Zhang SL; Chen HJ; Wang Z; Yan HH; Zhou Q; Tu HY; Zhang XC; Su J; Xie Z; Lizaso A; Chen SY; Lin X; Xiang JX; Wu YL; Yang JJ
Lung Cancer; 2020 Dec; 150():97-106. PubMed ID: 33126092
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of osimertinib resistance and emerging treatment options.
Schmid S; Li JJN; Leighl NB
Lung Cancer; 2020 Sep; 147():123-129. PubMed ID: 32693293
[TBL] [Abstract][Full Text] [Related]
36. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes.
Efremova M; Vento-Tormo M; Teichmann SA; Vento-Tormo R
Nat Protoc; 2020 Apr; 15(4):1484-1506. PubMed ID: 32103204
[TBL] [Abstract][Full Text] [Related]
37. Cancer statistics, 2020.
Siegel RL; Miller KD; Jemal A
CA Cancer J Clin; 2020 Jan; 70(1):7-30. PubMed ID: 31912902
[TBL] [Abstract][Full Text] [Related]
38. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
[TBL] [Abstract][Full Text] [Related]
39. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Leonetti A; Sharma S; Minari R; Perego P; Giovannetti E; Tiseo M
Br J Cancer; 2019 Oct; 121(9):725-737. PubMed ID: 31564718
[TBL] [Abstract][Full Text] [Related]
40. An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses.
Meraz IM; Majidi M; Meng F; Shao R; Ha MJ; Neri S; Fang B; Lin SH; Tinkey PT; Shpall EJ; Morris J; Roth JA
Cancer Immunol Res; 2019 Aug; 7(8):1267-1279. PubMed ID: 31186248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
